The Seventh International Congress on the Future of Breast Cancer is an international educational and scientific meeting that focuses on the clinical implications of breast cancer genetic and phenotypic subtyping. New data and promising studies that provide information about how to optimally individualize breast cancer therapy will be the highlights of the congress. Key topics in breast cancer diagnosis and management will be discussed and controversial issues debated in multiple faculty panel discussions. Strategies for optimizing the use of endocrine therapy, conventional chemotherapy, and agents targeting HER2 or angiogenic pathways will be discussed. Promising areas of translational research, as well as novel cytotoxic and biologic therapies, will also be presented. The format will include didactic sessions from thought leaders, question-and-answer panel discussions, and ample time for participant interaction with faculty.

At the conclusion of this congress, you should be able to:

• Discuss the key highlights from preclinical and clinical breast cancer research presented or published in the past year, including summaries from major international conferences
• Debate controversial issues in breast cancer care, including evolving prognostic and predictive factors, the use of novel techniques to assess response, novel therapies for locally advanced and metastatic breast cancer, the clinical utility of sentinel lymph node biopsy and other surgical approaches to localized disease, and novel radiation therapy techniques
• Explore new molecular techniques to subtype breast cancer and predict prognosis
• Describe the biology and therapeutic implications of different breast cancer subtypes
• Assess the utility of algorithms or genomic tools to assess recurrence risk and predict benefit from adjuvant chemotherapy, hormonal therapy, and HER2- targeted therapy for individual patients
• Review state-of-the-art treatments for early and advanced/metastatic breast cancer, including novel cytotoxic and biologic agents
• Appraise the potential clinical utility of serum, bone marrow, and breast cancer tissue–based diagnostic tests
• Summarize the various host-related factors, such as insulin, that affect breast cancer outcome
• Evaluate the growing number of treatments intended to reduce the shortand long-term toxicities associated with breast cancer therapy
• Identify important growth and survival pathways, including steroid hormone receptors, the HER/ErbB family, IGFR, and mediators of angiogenesis, as well as the agents that target those pathways
• Discuss the mechanisms of action of emerging chemotherapeutic and endocrine agents and their potential place in therapy
• Guide patients to promising clinical trials

This educational program is directed toward medical, surgical, and radiation oncologists practicing in the community or at academic institutions. Fellows, nurses, physician assistants, and pharmacists with an interest in the treatment of breast cancer are also invited to attend.

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 19 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.